MedTrace Logo

Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection

NCT01052259 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2014-01-08

No results posted yet for this study

Summary

The purpose of this study to examine the efficacy and safety of cycling treatment of deoxyspergualin in renal transplant patients with biopsy-proven chronic rejection.

Conditions

  • Chronic Rejection

Interventions

DRUG

Deoxyspergualin

100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.

Sponsors & Collaborators

  • Nippon Kayaku Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hiroshi Harada, Chief · Sapporo City General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
11 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01052259 on ClinicalTrials.gov